Contingency Management to Promote Smoking Abstinence in Cancer Patients

Medical University of South Carolina282 enrolled

Overview

This is a smoking cessation treatment study. Patients who have a cancer or a suspected cancer who will undergo surgical removal of their cancer are eligible to participate in this study. A novel smoking cessation treatment will be provided to half of the participants in the study. All study participants will receive standard smoking cessation therapy including counseling and the nicotine patch.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

282

Conditions

Smoking Cessation

Interventions

Contingency ManagementCOMBINATION_PRODUCT

Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.

Standard CareCOMBINATION_PRODUCT

Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age 18 or older 2. smoking 1 or more combustible tobacco products per day 3. diagnosed with or suspicion of any type of operable cancer Exclusion Criteria: 1. unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, or dementia 2. non-English speaking 3. use of alternative nicotine delivery systems (e.g., e-cigarettes, snus, etc) 4. pregnant women

Locations (1)

Medical University of South Carolina

Charleston, South Carolina, United States

Outcomes

Primary Outcomes

Abstinence Rates as Assessed by Self-report for Past 7 Days, Carbon Monoxide Breath Monitoring and/or Anabasine Testing

Abstinence will be defined by 7 days by self-report of no tobacco products, confirmed by CO breath test less than or equal to 4ppm and/or urine anabasine levels less than or equal to 2 ng/ml

Time frame: Changes between the study intake appointment to day of surgery, up to five weeks apart

Secondary Outcomes

Abstinence Rates as Assessed by Self-report for Past 7 Days, Carbon Monoxide Breath Monitoring and/or Anabasine Testing

Abstinence will be defined by 7 days by self-report of no tobacco products, confirmed by CO breath test less than or equal to 4ppm and/or urine anabasine levels less than or equal to 2 ng/ml

Time frame: Three months after surgery date

Abstinence Rates as Assessed by Self-report for Past 7 Days, Carbon Monoxide Breath Monitoring and/or Anabasine Testing

Abstinence will be defined by 7 days by self-report of no tobacco products, confirmed by CO breath test less than or equal to 4ppm and/or urine anabasine levels less than or equal to 2 ng/ml

Time frame: Six months after surgery date

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.